| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 03/27/2002 | EP1190101A1 Compositions and methods for preventing transepithelial transmission of hiv |
| 03/27/2002 | EP1190079A2 Control of gene expression in eukaryotic cells |
| 03/27/2002 | EP1190072A2 22012, a novel human carboxypeptidase |
| 03/27/2002 | EP1190059A1 Sgip peptides |
| 03/27/2002 | EP1190052A1 16405 receptor, a g-protein coupled receptor |
| 03/27/2002 | EP1190051A2 Human transport proteins |
| 03/27/2002 | EP1190049A1 Spliceosome protein and its use |
| 03/27/2002 | EP1190048A2 Novel candida albicans genes and proteins coded by said genes |
| 03/27/2002 | EP1189942A1 Somatostatin agonists |
| 03/27/2002 | EP1189941A1 Neuromedin b and somatostatin receptor agonists |
| 03/27/2002 | EP1189933A1 Echinocandin derivatives, method for preparing same and application as antifungal agents |
| 03/27/2002 | EP1189932A1 Novel echinocandin derivatives, method for preparing same and use as antifungal agents |
| 03/27/2002 | EP1189930A1 INHIBITORS OF THE INTEGRIN AlPHA V BETA 6 |
| 03/27/2002 | EP1189915A1 Process for the production of azithromycin |
| 03/27/2002 | EP1189914A1 DERIVATIVES OF 4'-DEMYCAROSYL-8a-AZA-8a-HOMOTYLOSIN |
| 03/27/2002 | EP1189913A1 Diphosphate salt of a 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin derivative and its pharmaceutical composition |
| 03/27/2002 | EP1189912A1 Novel crystalline forms of a macrolide antibiotic |
| 03/27/2002 | EP1189903A1 Novel benzo f]naphthyridine, preparation and compositions containing them |
| 03/27/2002 | EP1189891A1 Triazole compounds and combinatorial libraries thereof |
| 03/27/2002 | EP1189888A1 HETEROSUBSTITUTED PYRIDINE DERIVATIVES AS $i(PDE 4) INHIBITORS |
| 03/27/2002 | EP1189862A1 Preparation of substituted cyclopentane and cyclopentene compounds and certain intermediates |
| 03/27/2002 | EP1189645A2 Non-covalent bioconjugates useful for diagnosis and therapy |
| 03/27/2002 | EP1189633A2 Method for treating chronic hbv infection |
| 03/27/2002 | EP1189632A1 Pneumococcal surface protein combination vaccine |
| 03/27/2002 | EP1189630A1 A method of prophylaxis and treatment and agents useful for same |
| 03/27/2002 | EP1189624A1 Hla binding peptides and their uses |
| 03/27/2002 | EP1189622A2 Anionic polymers as toxin binders and antibacterial agents |
| 03/27/2002 | EP1189609A1 Cxcr-4 receptor antagonists - thrombopoietin mimetics |
| 03/27/2002 | EP1189603A2 Treatment of immune diseases like hiv disease and neoplastic disorders |
| 03/27/2002 | EP1189598A1 A method for the improvement of transport across adaptable semi-permeable barriers |
| 03/27/2002 | EP1189595A1 Ophthalmic compositions in form of aqueous gels |
| 03/27/2002 | EP1189583A1 Indole derivatives |
| 03/27/2002 | EP1189581A1 Topical anti-microbial compositions |
| 03/27/2002 | EP1189504A1 Pyrithione biocides enhanced by silver, copper, or zinc ions |
| 03/27/2002 | EP1077068B1 Utilization of interferon alpha 5 in the treatment of viral hepatopathies |
| 03/27/2002 | EP1047454A4 Methods of screening compounds useful for prevention of infection or pathogenicity |
| 03/27/2002 | EP1007534A4 Bh3 interacting domain death agonist |
| 03/27/2002 | EP0946176B1 The use of 7-(2-oxa-5,8-diazabicyclo 4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for manufacture of a medicament for the treatment of helicobacter pylori infections and associated gastroduodenal diseases |
| 03/27/2002 | EP0869809B1 Oxidized glutathione as cytokine and hemopoietic factor endogenous production enhancer |
| 03/27/2002 | EP0730470B1 Improved interferon polymer conjugates |
| 03/27/2002 | CN1342202A Soluble receptor BR43X2 and methods for using them for therapy |
| 03/27/2002 | CN1342196A Bifidobacterium in treatment of inflammatory disease |
| 03/27/2002 | CN1342171A Process for production of multiple cross-linked hyaluronic acid derivatives |
| 03/27/2002 | CN1342163A Ketolide antibiotics |
| 03/27/2002 | CN1342162A Substituted 2-acyl-3-(heteroaryl)-imidazo [1,2-a] pyrimidines, and related pharmaceutical compoistions and methods |
| 03/27/2002 | CN1342160A Crystal modification (of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-[4.3.0] nonan-8-yl)-6 Fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic |
| 03/27/2002 | CN1342156A Inhibition and treatment of hepatitis B virus and flavivirus by helioxanthin and its analogs |
| 03/27/2002 | CN1342145A Fused-ring compounds and use thereof as drugs |
| 03/27/2002 | CN1342088A Polypeptide comprising amino acid of AN N-terminal choline binding protein truncate, vaccine derived therefrom and uses thereof |
| 03/27/2002 | CN1342085A Inhibition of differentiation of cytotoxic T-cells by p-selecting ligand (PSGL) antagonists |
| 03/27/2002 | CN1342082A Use of tianeptin in production of medicaments to treat neurodegenerative pathologies |
| 03/27/2002 | CN1342079A Treatment and prevention of reactive oxygen metablite-mediated cellular damage |
| 03/27/2002 | CN1342078A Use of 3-isoxazolidinones and hydroxylamine acids for treatment of infections |
| 03/27/2002 | CN1342075A Liposome preparations |
| 03/27/2002 | CN1341666A Preparation of active oligosaccharides and their derivatives |
| 03/27/2002 | CN1341595A Nonviscous protein type synthetic compound or its carrier combined compound |
| 03/27/2002 | CN1341417A Injection medicine composite presciption containing cefotaxime and tazolepatan |
| 03/27/2002 | CN1081672C Fungicdal methods and compositions for killing yeast and sporular microorganisms |
| 03/27/2002 | CN1081641C Carbapenem derivatives and antimicrobials |
| 03/27/2002 | CN1081640C Diclavulanate salt of diamino ether and its preparing method |
| 03/27/2002 | CN1081639C Vinylpyrrolidinon cephalosporin derivatives |
| 03/27/2002 | CA2321348A1 Aromatic derivatives with hiv integrase inhibitory properties |
| 03/26/2002 | US6362342 Biosynthesis; drug libraries |
| 03/26/2002 | US6362322 Conversion of a watson-crick DNA to a hoogsteen-paired duplex |
| 03/26/2002 | US6362229 Inhibitors of multidrug transporters |
| 03/26/2002 | US6362228 Phenethyl-thiourea compounds and use |
| 03/26/2002 | US6362227 Methods for the treatment of tinnitus and other disorders using R(−)ketoptofen |
| 03/26/2002 | US6362191 Aminometyl oxooxazolidinyl benzene derivatives |
| 03/26/2002 | US6362190 Administering compounds such as 3-(2-phenylethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylene -carboxamidomethylpyridi nyl)-2-pyrazinone, n'-((1-(aminoiminomethyl)4-piperidinyl) methyl)-n-(3,3-diphenylpropionyl)-l-proline amide |
| 03/26/2002 | US6362181 Bactericides; enzyme inhibitors; antitumor agents |
| 03/26/2002 | US6362172 Water soluble prodrugs of azole compounds |
| 03/26/2002 | US6361997 Genetically modified CD34-negative adherently growing stem cells and their use in gene therapy |
| 03/26/2002 | US6361970 A polypeptide encoding an isoleucyl trna synthetase; therapy and screening antibiotic compounds |
| 03/26/2002 | US6361779 Transferrin receptor genes |
| 03/26/2002 | US6361778 Carboxyl terminal of papillomavirus L1 region is not required for formation of virus-like particles |
| 03/26/2002 | US6361776 Polypeptide isolated from mycobacterium vaccae comprising specified amino acid sequence, capable of eliciting and/or enhancing immune response to heterologous antigen |
| 03/26/2002 | US6361775 Compositions and methods for vaccines comprising α-galactosyl epitopes |
| 03/26/2002 | US6361769 Stimulation of host defense mechanisms against viral challenges |
| 03/26/2002 | US6361760 Aerosol composition comprising tricyclic compound or pharmaceutically acceptable salt thereof, liquefied hydrofluoroalkane and medium-chain fatty acid triglyceride |
| 03/26/2002 | CA2137551C A novel endothelial cell molecule mediating lymphocyte binding in man |
| 03/26/2002 | CA2097740C Product and process for treating bovine mastitis and bovine metritis |
| 03/26/2002 | CA2005925C Compositions and new pharmaceutical products for the regeneration of leucocytes and their use in the treatment of the immunodeficiency syndrome |
| 03/21/2002 | WO2002023186A2 System and method for optimizing drug therapy for the treatment of diseases |
| 03/21/2002 | WO2002022851A2 Novel tumor-associated marker |
| 03/21/2002 | WO2002022848A2 Compositions comprising mixtures of human cytokines and methods of producing the same |
| 03/21/2002 | WO2002022812A1 Methods of assaying or screening compound via detection of nuclear transport receptor inhibition by hepatitis c virus core protein |
| 03/21/2002 | WO2002022805A2 Modulation of il-2- and il-15-mediated t cell responses |
| 03/21/2002 | WO2002022790A1 T cell receptor transfer into a candidate effector cell or a precursor thereof |
| 03/21/2002 | WO2002022782A2 Homologous 28-kilodalton immunodominant protein genes of ehrlichia canis and uses thereof |
| 03/21/2002 | WO2002022687A2 Viral chemokine-tumur antigen fusion proteins |
| 03/21/2002 | WO2002022686A2 Defensin-antigen fusion proteins |
| 03/21/2002 | WO2002022682A1 Interferon-alpha induced gene |
| 03/21/2002 | WO2002022680A2 Site-specific, antibody-mediated activation of proapoptotic cytokine: amaice (antibody-mediated apoptosis inducing cytokine) |
| 03/21/2002 | WO2002022677A2 Variants of allergenic proteins of the group 2 of dermatophagoides |
| 03/21/2002 | WO2002022657A2 Peptide antagonist of multiple chemokine receptors and uses thereof |
| 03/21/2002 | WO2002022648A2 Compositions and methods for inducing specific cytolytic t cell responses |
| 03/21/2002 | WO2002022630A1 Purine derivatives |
| 03/21/2002 | WO2002022614A1 Quinolizine derivatives |
| 03/21/2002 | WO2002022613A1 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents |
| 03/21/2002 | WO2002022612A1 Thiazolidine derivatives and its use as antifungal agent |